Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: This large, multinational study aimed to confirm in a community practice setting the efficacy and safety of cetuximab plus irinotecan in patients with epidermal growth factor–expressing metastatic colorectal cancer (mCRC) who had recently failed an irinotecan-containing regimen. Patients and Methods: The primary objective was to determine the progression-free survival (PFS) rate at 12 weeks. The initial cetuximab dose was 400 mg/m 2 and was followed weekly by 250 mg/m 2; irinotecan (according to prestudy regimen) was given weekly (125 mg/m 2 weekly for 4 of 6 weeks), every 2 weeks (180 mg/m 2 each), or every 3 weeks (350 mg/m 2 each). Results: The intention-to-treat/safety population comprised 1,147 treated patients who received irinotecan weekly (n = 93); every 2 weeks (n = 670); every 3 weeks (n = 356); or another dose (n = 28). The PFS rate at 12 weeks was 61%, and the median survival was 9.2 months. Treatment was generally well tolerated. The most common treatment-related grades 3 to 4 adverse events were diarrhea (19%), neutropenia (10%), rash (7%), and asthenia (6%). The rate of grades 3 to 4 infusion-related reactions (IRRs; composite adverse event category) was 1% for patients who received both antihistamine and corticosteroid premedication. Conclusion: Tolerability (except IRR incidence), PFS rate, and overall survival rate were in line with previous results. At 1%, the rate of IRRs in patients who received prophylactic premedication with both antihistamine and corticosteroid is lower than previously reported. MABEL clearly confirms in a community practice setting the efficacy and safety of cetuximab plus irinotecan in the treatment of mCRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationSaltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694 · cited 1×
“By using current immunohistochemistry methods, EGFR expression can be detected in 75% to 89% of colorectal cancers (CRCs).(2-6) Cetuximab interacts with the extracellular domain of this transmembrane protein, partially occludes the ligand binding region, and sterically prevents the receptor from adopting the extended…”
MethodA Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Cited by
Douillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809
Self-citationWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Self-citationSchmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Self-citationCunningham, D., Atkin, W., Lenz, H.-J., Lynch, H. T., Minsky, B., Nordlinger, B., & Starling, N. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60353-4 · Cited by 1,351
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
Frattini, M., Saletti, P., Romagnani, E., Martin, V, Molinari, F., Ghisletta, M., Camponovo, A., Etienne, L. L., Cavalli, F., & Mazzucchelli, L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604009 · Cited by 540
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
Martinelli, E., De Palma, R., Orditura, M., De Vita, F., & Ciardiello, F. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03992.x · Cited by 333
Fakih, M., & Wong, R. (2010) · Current Oncology · doi:10.3747/co.v17is1.616 · Cited by 76
Metadata
- Authors
- Wilke, H., Glynne-Jones, R., Thaler, J., Adenis, A., Preusser, P., Aguilar, E. A., Aapro, M. S., Esser, R., Loos, A. H., & Siena, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-11-20
- Volume
- 26
- Issue
- 33
- Pages
- 5335-5343
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2164055979
- Cited by
- 104
- References
- 3
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.